Section
A newly developed weighted flare scoring system in SLE accurately predicts organ damage accumulation, outperforming traditional flare classifications and informing treat-to-target strategies.
Centralized clinical and imaging evaluation via telemedicine significantly improves diagnostic accuracy in patients suspected of axial spondyloarthritis, reducing misdiagnoses and guiding more precise patient management.
This article explores the differential associations of mosaic chromosomal alterations (mCAs), especially chromosomal loss and mosaic loss of the X chromosome, with systemic sclerosis and its subtypes, revealing phenotype-specific genetic co
This study explores the association between inducible laryngeal obstruction (ILO) and symptoms in patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD), highlighting chronic cough, dysphagia, and
A validated set of 17 quality indicators (QIs) for lupus nephritis, derived from the 2025 EULAR recommendations, shows variable adherence in practice and an association between higher adherence and lower damage accrual in a tertiary-care co
A large single-center cohort study found no increased incidence of malignancy in patients with IgG4-related disease (IgG4-RD). Smoking and older age increased malignancy risk, while female sex and submandibular gland involvement were protec
The 2026 EULAR update modernizes how recommendations and points-to-consider for rheumatic and musculoskeletal diseases are developed — formalizing patient partnership, living guidance, robust evidence synthesis, cost-awareness and transpare
This study reveals that exposure to fine particulate matter (PM2.5) significantly increases disease activity and flare risk in rheumatoid arthritis patients, highlighting the importance of air quality in disease management.
This study reveals mycophenolate and azathioprine do not improve 3-year transplant-free survival or lung function in fibrotic ILD, with potential harm in select subtypes. Robust randomized trials remain essential for guiding immunosuppressi
A risk prediction model derived from the PEXIVAS trial estimates the 2-year relapse probability in ANCA-associated vasculitis, integrating clinical and laboratory factors to improve individualized patient management.
This study identifies serum and gene expression signatures predicting successful canakinumab tapering in systemic juvenile idiopathic arthritis, offering precision medicine strategies to reduce flares.
This multicenter study identifies a unique pustular psoriasis flare phenotype occurring after biologic therapy withdrawal in plaque psoriasis, detailing clinical characteristics and independent risk factors to guide vigilant monitoring and
MRI-detected hand tenosynovitis and ultrasound-detected bone erosions independently and jointly predict progression to inflammatory arthritis in anti-CCP positive individuals with musculoskeletal symptoms but no clinical synovitis.
Dapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.
This study identifies neutrophil-dependent type-I interferon responses and NETs as key drivers of joint damage in hemophilia A, opening avenues for novel therapies to prevent hemophilic arthropathy.
A 12-week randomized trial compared the effects of calorie-restricted DASH, carbohydrate-restricted, and low-purine diets on weight loss and serum urate levels in men with overweight or obesity and hyperuricemia, highlighting adherence and
A recent randomized trial shows that adding intravenous immunoglobulin (IVIG) to high-dose prednisone significantly improves muscle strength and disease activity in newly diagnosed idiopathic inflammatory myopathies with rapid and clinicall
A nationwide observational study reveals tocilizumab use in giant cell arteritis significantly lowers major adverse cardiovascular events compared to methotrexate, highlighting its potential cardiovascular benefits beyond inflammation contr
Deucravacitinib, an oral selective TYK2 inhibitor, demonstrates significant suppression of interferon and B-cell pathway biomarkers in active SLE patients, supporting ongoing phase 3 trials for this challenging autoimmune disease.
This study assesses whether the administration route of glucocorticoids in early rheumatoid arthritis influences continued steroid use and advanced therapy initiation at one year.
